New York State Common Retirement Fund’s Cascadian Therapeutics, Inc. CASC Stock Holding History

New York State Common Retirement Fund’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-36,500	Closed	-$135K	–	3100
2017 Q4	$135K	Hold	36,500	–	–	﹤0.01%	2912
2017 Q3	$149K	Hold	36,500	–	–	﹤0.01%	2911
2017 Q2	$136K	Buy	+36,500	New	+$145K	﹤0.01%	3021
2016 Q2	–	Sell	-14,033	Closed	-$107K	–	3230
2016 Q1	$107K	Hold	14,033	–	–	﹤0.01%	2912
2015 Q4	$187K	Hold	14,033	–	–	﹤0.01%	2801
2015 Q3	$231K	Sell	14,033 -2,852	-17%	-$58.5K	﹤0.01%	2713
2015 Q2	$379K	Buy	+16,885	New	+$267K	﹤0.01%	2650

New York State Common Retirement Fund's CASC Position: Q1 2018 in Review

New York State Common Retirement Fund sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 36,500 shares — an estimated $135K sold.

New York State Common Retirement Fund first reported a position in CASC in Q2 2015 and held it in 7 quarters. The position peaked at $379K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

New York State Common Retirement Fund reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
New York State Common Retirement Fund sold 36,500 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $135K.
New York State Common Retirement Fund first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 7 quarters.
New York State Common Retirement Fund's Cascadian Therapeutics, Inc. position peaked at $379K in Q2 2015.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on New York State Common Retirement Fund's 13F filing for Q1 2018, filed 10 May 2018.